Skip to content

Ropivacaine verses bupivacaine for urological surgeries.

A randomised comparative study of equipotent dose of hyperbaric Ropivacaine and hyperbaric Bupivacaine for subarachnoid block for transurethral resection of prostate ( TURP).

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/09/045865
Enrollment
50
Registered
2022-09-26
Start date
Unknown
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Ropivacaine: Injection Ropivacaine 3.5 ml given in subarachnoid space for urological surgeries (TURP) Control Intervention1: Bupivacaine: Injection bupivacaine 3.5 ml in subarachnoid sp

Sponsors

Rajendra institute of medical sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Posted for urological surgeries whose anticipated time of surgery is 2 hours.

Exclusion criteria

Exclusion criteria: Patient refusal Any contraindication for spinal anesthesia Patients with previous abdominal surgeries Known drug allergy Patients having a body weight >70 kg. Bleeding disorders Neurlogical disease Local skin infections Severe back deformities, Raised intracranial pressure.

Design outcomes

Primary

MeasureTime frame
1.To assess and compare the hemodynamic profile and block characteristics of hyperbaric ropivacaine 0.75% with hyperbaric bupivacaine 0.5% in urological surgeries.Timepoint: Base line: at induction First pain sensation: 2-3 hrs Second recording: 6 hrs Third recording: 24 hrs

Secondary

MeasureTime frame
1. To evaluate pain scores in post operative period. 2. To enable faster ambulation. 3. To improve recovery profile and faster discharge. Timepoint: From induction to first 24 hours and discharge.

Countries

India

Contacts

Public ContactDr Tushar Kumar

Rajendra institute of medical sciences

dr.tushar.kumar@gmail.com9472758699

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026